SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-067040
Filing Date
2023-11-30
Accepted
2023-11-30 16:15:24
Documents
17
Period of Report
2023-11-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xene-20231129.htm   iXBRL 8-K 56580
2 EX-1.1 xene-ex1_1.htm EX-1.1 480524
3 EX-4.1 xene-ex4_1.htm EX-4.1 106415
4 EX-5.1 xene-ex5_1.htm EX-5.1 17050
5 GRAPHIC img3998686_0.jpg GRAPHIC 13515
6 GRAPHIC img3998686_1.jpg GRAPHIC 26886
  Complete submission text file 0000950170-23-067040.txt   940858

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xene-20231129.xsd EX-101.SCH 2486
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xene-20231129_pre.xml EX-101.PRE 11111
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xene-20231129_lab.xml EX-101.LAB 17902
11 EXTRACTED XBRL INSTANCE DOCUMENT xene-20231129_htm.xml XML 4669
Mailing Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W
Business Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W (604) 484-3300
Xenon Pharmaceuticals Inc. (Filer) CIK: 0001582313 (see all company filings)

IRS No.: 980661854 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36687 | Film No.: 231456039
SIC: 2834 Pharmaceutical Preparations